Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Endeavor Biomedicines, Inc.
Eli Lilly and Company
Servier
Stanford University
Milton S. Hershey Medical Center
Mayo Clinic
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwell Health
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Lumos Pharma
Washington University School of Medicine
University of Alabama at Birmingham
Deciphera Pharmaceuticals, LLC
Eisai Inc.
Novartis
M.D. Anderson Cancer Center
Columbia University
Center Trials & Treatment Europe
Celgene
Duke University
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Baylor College of Medicine
National Cancer Institute (NCI)
DNAtrix, Inc.
Celgene
Duke University
Biogen
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Lumos Pharma
Emory University
University of California, Davis
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Alliance for Clinical Trials in Oncology
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
European Organisation for Research and Treatment of Cancer - EORTC
University of Washington